Evidence Table E44. Binge eating disorder behavioral and drug treatment – part 8

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Agras, 199449 | Weight, kg | Weight, mean (SD)PretreatmentG1: 111.9 (17.4)G2: 102.1 (15.7)G3: 102.9 (15.8)p=NS | Weight, mean (SD)12 wksG1: 112.7 (18.5)G2: 102.7 (16.5)G3: 100.9 (16.8)G1 and G2 < G3, p<0.0524 wksG1: 107.0 (20.1)G2: 100.7 (16.7)G3: 100.4 (17.3)p=NS36 wksG1: 105.9 (20.5)G2: 100.5 (17.6)G3: 99.2 (16.9)p=NS% Weight change, group X time, p<0.0013 month f/uG1: Lost 4.8 kg from baselineG2: No change in weight from baselineG3: Lost 4.15kg from baselinep=NS | NR | NR | NR |

Evidence Table E44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Brambilla, 200950 | NA | BMI, mean (SD)G1: 39 (6)G2: 34 (6)G3: 34 (5)Weight (kg), mean (SD)G1: 105 (13)G2: 86 (14)G3: 88 (13) | BMI, mean (SD)G1: 35 (6)G2: 32 (8)G3: 34 (8)Group X time, p=0.01Weight (kg), mean (SD)G1: 93 (12)G2: 84 (16)G3: 87 (13)Group X time, p=0.00 | 6m BMIG1: 35 (SD 6), r=0.91 (table 2 reports significance as r)G2: 32 (SD 8), r=NS (table 2 reports significance as r)G3: 34 (SD 8), r=NSOne-way ANOVA showed significant decrease in BMI (p=0.00001) in G1 onlyTwo-way ANOVA for repeated measures showed significant effect of group (p=0.03, F=3.2), time (p=0.01, F=2.26) and group per time (p=0.01, F=2.26) on changes in BMI in the 3 groups6m Weight (kg)G1: 93 (SD 12), r=0.91 (table 2 reports significance as r)G2: 84 (SD 16), r=NS (table 2 reports significance as r) | NA | NA |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Brambilla, 200950(continued) |  |  |  | G3: 87 (SD 13), r=NS (table 2 reports significance as r)One-way ANOVA showed significant decrease in weight (p=0.00001) in G1 onlyTwo-way ANOVA for repeated measures showed significant effect of group (p=0.05, F=2.99), time (p=0.00003, F=5.45) and group per time (p=0.0017, F=3.42) on changes in weight in the 3 groupsCorrelation analysis (Spearman's test):G1: reduction in weight correlated negatively with change in EDI-2 perfectionism (p=0.04, T=-2.4), social insecurity (p=0.01, T=-3.0), and PDQ-4-R negativism (p=0.05, T=-2.25) |  |  |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Brambilla, 200950(continued) |  |  |  | G2: reduction in weight correlated positively with EDI-2 ineffectiveness (p=0.02, T=2.86)G3: reduction in weight correlated negatively with SCL-90-R obsessivity-compulsivity (p=0.05, T=-2.5) and psychoticism (p=0.02, T=-3.2)Article also states that "no correlations emerged between weight changes and PDQ-4-R data," although this contradicts the significant correlation found between G1 and PDQ-4-R negativism |  |  |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Claudino, 200751 | Weight, kgBody Mass Index (BMI) | Weight, mean (SD)G1: 96.6 (16.7)G2: 98.4 (10.9)p = 0.23BMI, mean (SD)G1: 37.4 (4.9)G2: 37.4 (3.5)p = 0.93 | Weight, mean (SD)G1: 89.8 (13.4)G2: 97.5 (10.5)Group X time rate of change, p < 0.001BMI, mean (SD)G1: 35.0 (3.5)G2: 36.7 (4.7)Group X time rate of change, p = 0.0002 | NA | NA | NA |
| Devlin, 200752Devlin, 200553 | Weight (kg) | Pre-treatment weight (kg) mean (SD)Overall: 115 (21.8)G1: 116.9 (20.8)G2: 116.5 (22.2)G3: 113.8 (22.9)G4: 113.5 (22.2) | Post-treatment weight (kg) mean (SD)Overall: 113 (23.6)G1: 112.8 (22.7)G2: 114.6 (23.0)G3: 111.9 (27.1)G4: 111.1 (21.9)Group X time, p=NS6 months weight (kg) mean (SD)Overall: 111 (23.2)G1: NRG2: NRG3: NRG4: NR12 months weight (kg) mean (SD)Overall: 111 (23.2)G1: NRG2: NRG3: NRG4: NR | NA | NA | NA |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Devlin, 200752Devlin, 200553(continued) |  |  | 18 months weight (kg) mean (SD)Overall: 113 (23.2)G1: NRG2: NRG3: NRG4: NR24 months weight (kg) mean (SD)Overall: 115 (23.6)G1: NRG2: NRG3: NRG4: NREstimated change in weight over 24 months mean (SE): 0.484 (0.309)G1: NRG2: NRG3: NRG4: NRIndividual CBT (G1&G3 vs. G2&G4): F=0.01, p=0.911Medication: (G1&G2 vs. G3&G4): F=0.01, p=0.914Time: F=2.46, p=0.119CBT-by-time: NSMedication-by-time: NS |  |  |  |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Golay, 200554 | Body fat mass-bioelectrical impedence, %Waist circumference, cmHip circumference, cmTotal energy expenditure [kcal/d] | Body fat mass-bioelectrical impedenceG1: 44.6 (0.9)G2: 44.7 (1.0)p = NRWaist circumference, mean (SEM)G1: 103.7 (1.8)G2: 107.0 (1.6)p = NRHip circumference, mean (SEM)G1: 121.1 (9.2)G2: 120.3 (9.5)p = NRTotal energy expenditure, mean (SEM)G1: 2275 (344.7)G2: 2385 (356.0)p = NR | Body fat mass-bioelectrical impedence, %G1: 41.3 (1.0)G2: 43.1 (1.0)p = 0.023Waist circumference, mean (SEM)G1: 96.5 (1.8)G2: 101.0 (1.5)p = 0.005Hip circumference, mean (SEM)G1: 114.5 (8.2)G2: 116.6 (9.3)p < 0.001Total energy expenditure, mean (SEM)G1: 2158 (327.0)G2: 2238 (334.0)p = NS | Total cholesterol, mMLow-density cholesterol (LDL), mMHigh-density cholesterol (HDL), mMTriglycerides, mMSystolic Blood Pressure (SBP), mmHgDiastolic BP (DBP), mmHgGlucose, mg/dLInsulin, pMLeptin, micrograms/L | Total cholesterol, mean (SEM)G1: 5.8 (0.9)G2: 5.8 (0.9)p = NRLDL, mean (SEM)G1: 3.5 (0.5)G2: 3.6 (0.5)p = NRHDL, mean (SEM)G1: 1.5 (0.2)G2: 1.4 (0.2)p = NRTriglycerides, mean (SEM)G1: 1.7 (0.2)G2: 1.8 (0.3)p = NRSBP, mean (SEM)G1: 123.2 (18.6)G2: 122.1 (18.2)p = NRDBP, mean (SEM)G1: 81.1 (12.3)G2: 80.5 (12.0)p = NRGlucose, mean (SEM)G1: 5.8 (0.9)G2: 6.0 (0.9)p = NRInsulin, mean (SEM)G1: 147.0 (22.3)G2: 137.5 (20.5)p = NR | Total cholesterol, mean (SEM)G1: 5.3 (0.8)G2: 5.7 (0.9)p = 0.029LDL, mean (SEM)G1: 3.4 (0.5)G2: 3.6 (0.5)p = 0.090HDL, mean (SEM)G1: 1.4 (0.2)G2: 1.4 (02)p = NSTriglycerides, mean (SEM)G1: 1.2 (0.2)G2: 1.5 (0.2)p = 0.067SBP, mean (SEM)G1: 122.0 (18.2)G2: 121.5 (18.0)p = NSDBP, mean (SEM)G1: 78.0 (11.8)G2: 81.7 (12.4)p = 0.048Glucose, mean (SEM)G1: 5.5 (0.8)G2: 5.9 (0.9)p = 0.070Insulin, mean (SEM)G1: 114.5 (17.3)G2: 144.4 (21.5)p = 0.045 |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Golay, 200554(continued) |  |  |  |  | Leptin, mean (SEM)G1: 28.8 (4.4)G2: 27.1 (4.0)p = NR | Leptin, mean (SEM)G1: 23.6 (3.6)G2: 23.9 (3.6)p = NS |
| Grilo, 200555 | BMIWeight lossPercentage weight loss5% weight loss | BMIG1: 36.2 (SD 4.7)G2: 36.8 (SD 5.1)p=0.67 | Post-treatment BMIG1: NRG2: NRp=NR3m BMIG1: NRG2: NRp=NRPost-treatment Weight loss (kg)G1: 3.5 (SD 3.5)G2: 1.6 (SD 2.4)F=5.57p=0.023m Weight loss (kg), meanG1: 3.4 (SD 5.0)G2: 1.3 (SD 3.1)F=3.05p=0.09Post-treatment % weight lossG1: 3.3 (SD 3.3)G2: 1.6 (SD 2.4)F=4.52p=0.043m % weight lossG1: 3.3 (SD 5.0)G2: 1.3 (SD 3.0)F=2.69p=0.10 | NA | NA | NA |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Grilo, 200555(continued) |  |  | Post-treatment 5% weight loss, ITT analysisG1: 36%G2: 8%chi-square=5.711p=0.0173m 5% weight loss, ITT analysisG1: 32%G2: 8%chi-square=4.50p=0.034Post-treatment 5% weight loss, completersG1: 47%G2: 10%chi-square=6.72p=0.013m 5% weight loss, completersG1: 42%G2: 10%chi-square=5.27p=0.022 |  |  |  |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Grilo, 201356 | Body Mass Index (BMI) | BMI, meanG1: 39.0 (SD 7.0)G1: 37.2 (SD 5.3)p=NR, NS | Post-treatment BMIG1: 37.9 (SD 6.9)G2: 36.0 (SD 5.0)Groups did not differ significantly in improvements (p=NR, NS)6m BMIG1: 37.6 (SD 5.7)G2: 36.7 (SD 5.3)Groups did not differ significantly in improvements (p=NR, NS) | NA | NA | NA |
| Grilo, 200557Grilo, 201258Grilo, 201259Grilo, 200660 | Body Mass Index (BMI)Weight loss, lbs | BMI, mean (SD)G1: 38.9 (9.5)G2: 35.7 (7.2)G3: 35.7 (8.3)G4: 35.0 (6.2)F:1.30p=0.279 | BMI, mean (SD):G1: 38.1 (9.6) G2: 35.7 (7.5)G3: 34.9 (7.9)G4: 34.2 (5.8)ANCOVA p=nsG2 v G1: p=naG4 v G3: p=naG4 v G2: p=naG4 v G1: p=naG3 v G2: p=naG3 v G1: p=na6-month followupG1: 36.1 (0.6)G3: 36.9 (0.6)G4: 35.9 (0.5)12-month followupG1: 36.2 (0.6)G3: 35.8 (0.6)G4: 34.8 (0.5) | NR | NR | NR |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Grilo, 200557Grilo, 201258Grilo, 201259Grilo, 200660(continued) |  |  | Mixed-model, p=NR, stated = significantG4 v. G3: p=0.253G4 v. G1: p=0.313G3 v. G1: p=0.908Weight loss, estimated marginal mean(SE)Post-treatmentG1: -4.8 (3.0) G3 -5.6 (2.9)G4 -5.0 (2.8)6-month followupG1: -2.3 (3.6)G3: -2.8 (3.1)G4: -2.8 (3.1)12-month followupG1: -1.5 (3.5)G3: -4.1 (3.6)G4: -9.8 (3.2)Mixed-model, p=NR, stated = significantG4 v. G3: p=0.350G4 v. G1: p=0.405G3 v. G1: p=0.929 |  |  |  |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Laederach-Hofmann, 199961 | Weight, kgBody mass index (BMI) | Weight, mean (SD)G1: 96.0 (14.2)G2: 114.8 (29.5)p<0.05BMI, mean (SD)G1: 36.1 (6.3)G2: 43.2 (9.4p<0.02 | Weight, mean (SD)8 wksG1: 93. 8(14.4)G2: 113.0 (29.4)% change (data in figure), p < 0.0532 wksG1: 90.8 (13.5)G2: 117.0 (29.2)% change (data in figure), p=0.0003BMI, mean (SD)NR | Waist to hip ratioBlood pressure, systolic (mmHg)Blood pressure, diastolic (mmHg)Serum glucose (mmol/l)Total serum cholesterol (mmol/l) | Waist to hip ratio, mean (SD)G1: 0.96 (0.007)G2: 1.01 (0.07)p=NSBlood pressure, systolic (mmHg):G1: 132.2 (18.0)G2: 131.4 (13.5)p=NSBlood pressure, diastolic (mmHg)G1: 87.0 (9.4)G2: 87.5 (9.1)p=NSSerum glucose (mmol/l)G1: 5.6 (1.2)G2: 5.7 (1.3)p=NSTotal serum cholesterol (mmol/l)G1: 5.3 (1.1)G2: 5.5 (0.9)p=NS | "Systolic and diastolic blood pressure, serum cholesterol, and gluclose concentration as well as the other hematochemical parameters and wait-to-hip ratio remained stable during the 8-week study in both groups." |
| Lanzarone, 201462 | Percentage weight loss |  |  |  |  |  |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Molinari, 200563 |  | n/a | 3m achieved weight loss of at least 5% of initial weightG1: 100%G2: 100%G3: 100%6m % weight lossG1: 5.25 (SD 1.30)G2: 6.62 (SD 2.74)G3: 7.32 (SD 0.88)p=NR, NS12m % weight lossG1: 7.53 (SD 3.57)G2: 0.19 (SD 2.74)G3: 6.78 (SD 3.94)p=0.001 | NA | NA | NA |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Ricca, 200164 | 5% weight loss | BMI Overall: 32.3 (SD 5.8)G1: 32.0 (SD 6.0)G2: 31.7 (SD 5.6)G3: 32.5 (SD 6.1)G4: 32.1 (SD 3.8)G5: 32.7 (SD 4.1) | 24 weeks (end of treatment) (presented in bar graph only so means not discernable)G1: NR, p<0.01 vs. baselineG2: NR, p<0.01 vs. baselineG3: NR, p<0.01 vs. baselineG4: NRG5: NR1 year after end of treatment (presented in bar graph only so means not discernable)G1: NR, p<0.01 vs. baselineG2: NR, p<0.01 vs. baselineG3: NR, p<0.01 vs. baselineG4: NRG5: NRG1, G2, and G3 showed increased BMI compared with 24wk but significantly lower than baseline; G4 and G5 showed no significant difference in 1y vs. baseline | NA | NA | NA |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Ricca, 200965 | Body mass index (BMI) | BMIG1: 39.21 (SD 7.82)G2: 38.43 (SD 5.70) | 24wk BMIG1: 38.41 (SD 7.67)G2: 36.77 (SD 5.84)G2 had greater reduction, p<0.0118m BMIG1: 38.99 (SD 7.02)G2: 36.49 (SD 5.96)p=NR | NA | NA | NA |